Recurrent herpes zoster in a rheumatoid arthritis patient treated with tofacitinib: A case report and review of the literature

BACKGROUND: Tofacitinib is an oral Janus kinase (JAK) inhibitor that is currently approved by the United States Food and Drug Administration for the treatment of rheumatoid arthritis (RA). Varicella zoster virus reactivation leading to herpes zoster (HZ) is an adverse effect of this drug; however, r...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Qing-Xia, Meng, Hui-Juan, Pang, Yun-Yan, Qu, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9453357/
https://www.ncbi.nlm.nih.gov/pubmed/36157812
http://dx.doi.org/10.12998/wjcc.v10.i24.8703

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9453357/
https://www.ncbi.nlm.nih.gov/pubmed/36157812
http://dx.doi.org/10.12998/wjcc.v10.i24.8703

Ejemplares similares